» Articles » PMID: 37322479

Combination Effects of Amino Acid Transporter LAT1 Inhibitor Nanvuranlat and Cytotoxic Anticancer Drug Gemcitabine on Pancreatic and Biliary Tract Cancer Cells

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2023 Jun 15
PMID 37322479
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cytotoxic anticancer drugs widely used in cancer chemotherapy have some limitations, such as the development of side effects and drug resistance. Furthermore, monotherapy is often less effective against heterogeneous cancer tissues. Combination therapies of cytotoxic anticancer drugs with molecularly targeted drugs have been pursued to solve such fundamental problems. Nanvuranlat (JPH203 or KYT-0353), an inhibitor for L-type amino acid transporter 1 (LAT1; SLC7A5), has novel mechanisms of action to suppress the cancer cell proliferation and tumor growth by inhibiting the transport of large neutral amino acids into cancer cells. This study investigated the potential of the combined use of nanvuranlat and cytotoxic anticancer drugs.

Methods: The combination effects of cytotoxic anticancer drugs and nanvuranlat on cell growth were examined by a water-soluble tetrazolium salt assay in two-dimensional cultures of pancreatic and biliary tract cancer cell lines. To elucidate the pharmacological mechanisms underlying the combination of gemcitabine and nanvuranlat, we investigated apoptotic cell death and cell cycle by flow cytometry. The phosphorylation levels of amino acid-related signaling pathways were analyzed by Western blot. Furthermore, growth inhibition was examined in cancer cell spheroids.

Results: All the tested seven types of cytotoxic anticancer drugs combined with nanvuranlat significantly inhibited the cell growth of pancreatic cancer MIA PaCa-2 cells compared to their single treatment. Among them, the combined effects of gemcitabine and nanvuranlat were relatively high and confirmed in multiple pancreatic and biliary tract cell lines in two-dimensional cultures. The growth inhibitory effects were suggested to be additive but not synergistic under the tested conditions. Gemcitabine generally induced cell cycle arrest at the S phase and apoptotic cell death, while nanvuranlat induced cell cycle arrest at the G0/G1 phase and affected amino acid-related mTORC1 and GAAC signaling pathways. In combination, each anticancer drug basically exerted its own pharmacological activities, although gemcitabine more strongly influenced the cell cycle than nanvuranlat. The combination effects of growth inhibition were also verified in cancer cell spheroids.

Conclusions: Our study demonstrates the potential of first-in-class LAT1 inhibitor nanvuranlat as a concomitant drug with cytotoxic anticancer drugs, especially gemcitabine, on pancreatic and biliary tract cancers.

Citing Articles

Methionine metabolite spermidine inhibits tumor pyroptosis by enhancing MYO6-mediated endocytosis.

Wu J, Ding C, Zhang C, Xu Z, Deng Z, Wei H Nat Commun. 2025; 16(1):2184.

PMID: 40038267 PMC: 11880502. DOI: 10.1038/s41467-025-57511-4.


Pharmacological and structural insights into nanvuranlat, a selective LAT1 (SLC7A5) inhibitor, and its N-acetyl metabolite with implications for cancer therapy.

Jin C, Zhou X, Xu M, Okanishi H, Ohgaki R, Kanai Y Sci Rep. 2025; 15(1):2903.

PMID: 39849059 PMC: 11758009. DOI: 10.1038/s41598-025-87522-6.


Leucine drives LAT1-related SNAIL upregulation in glucose-starved pancreatic cancer cells.

Masubuchi H, Imamura Y, Kawaguchi T, Koga H Med Mol Morphol. 2024; 58(1):23-33.

PMID: 39240293 DOI: 10.1007/s00795-024-00404-0.


Impact of genetic variants in the solute carrier () genes encoding drug uptake transporters on the response to anticancer chemotherapy.

Marin J, Serrano M, Herraez E, Lozano E, Ortiz-Rivero S, Perez-Silva L Cancer Drug Resist. 2024; 7:27.

PMID: 39143954 PMC: 11322974. DOI: 10.20517/cdr.2024.42.


L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer.

Norrsell R, Bauden M, Andersson R, Ansari D Cancer Control. 2024; 31:10732748241251583.

PMID: 38683590 PMC: 11060026. DOI: 10.1177/10732748241251583.


References
1.
Undevia S, Gomez-Abuin G, Ratain M . Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005; 5(6):447-58. DOI: 10.1038/nrc1629. View

2.
Cormerais Y, Pagnuzzi-Boncompagni M, Schrotter S, Giuliano S, Tambutte E, Endou H . Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. J Cell Mol Med. 2019; 23(4):2711-2718. PMC: 6433660. DOI: 10.1111/jcmm.14176. View

3.
Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K . Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012; 107(4):632-8. PMC: 3419959. DOI: 10.1038/bjc.2012.310. View

4.
Kanai Y . Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther. 2021; 230:107964. DOI: 10.1016/j.pharmthera.2021.107964. View

5.
Ito D, Fujimoto K, Mori T, Kami K, Koizumi M, Toyoda E . In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 2005; 118(9):2337-43. DOI: 10.1002/ijc.21532. View